Name: EASTON PHARMACEUTICALS INC. Status: Active Filing ID: 2012-000626615 Sub Status: Current Type: Profit Corporation - Domestic Standing - Tax: Good Old Name: Standing - RA: Good Fictitious Name: Standing - Other: Good Sub Type:
Formed in: Wyoming Initial Filing: 07/30/2012 Term of Duration: Perpetual Delayed Effective Date: Purpose Code: Inactive Date: Principal Office: 425 University Ave Ste 600 Toronto Ontario M5G1T6 , Canada Mailing Address: 425 University Ave Ste 600 Toronto Ontario M5G1T6 , Canada ADDITIONAL DETAILS HISTORY PUBLIC NOTES PARTIES ADDITIONAL DETAILS Registered Agent: 007 Agents, Inc. Agent Address: 1876 Horse Creek Rd Cheyenne, WY 82009 USA Latest AR/Year: 01891385 / 2013 AR Exempt: N License Tax Paid: $50.00 Preferred Shares: Preferred Par Value: Common Shares: 250,000,000 Common Par Value: $0.001
Entity Detail PDF - Print a copy of this Business Entity detail
EAPH,all in one DD,Could see 30 cents here: first immense market potential per this: Aug,23 pr is very primed:
1. "has entered into discussions with 2 private independent companies in Canada for a proposed joint venture or partnership where it would share in any revenues generated in the medical Marijuana industry. Both of the companies currently possess growers licenses within various Provinces in Canada with one of them having affiliations within a clinical marijuana friendly state."
2. Laws currently sitting in other States were expected to have been heard and acted on but were put on hold until sometime later in 2013 or early 2014.
skies the limit here,he medical Marijuana industry could reach nearly $9 billion nationwide in five years, as more states in the United States clear the way to likely legalize marijuana for medicinal purposes
"owned fifteen U.S. patents, nine foreign patents, five U.S. patent applications and numerous international patent applications designating over 100 foreign countries with claims relating to our sustained release delivery matrix system, systems containing drug preparations, uses of the systems for various treatment therapies and addiction therapeutic program. The patents were to expire between 2015 and 2018".
Easton Pharmaceuticals is based in Toronto, Ontario, Canada with a manufacturing partner in a 100,000 sq. ft. FDA approved facility in New Jersey, United States."
NOW READ THIS:
INSIDERS,"CEO & V.P. of AXXESS PHARMACEUTICAL AXXE ($1.00 pps) EACH OWN 10,000,000 RESTRICTED SHARES, THAT IS 20,000,000.. "
EAPH has some HUGE pending news and a breakout chart ready to explode from its 200 ma $$$
BIG PENDING MJ NEWS and the MJ sector is back inplay now $$$
from Aug,23 pr
1. "has entered into discussions with 2 private independent companies in Canada for a proposed joint venture or partnership where it would share in any revenues generated in the medical Marijuana industry. Both of the companies currently possess growers licenses within various Provinces in Canada with one of them having affiliations within a clinical marijuana friendly state."
2. Laws currently sitting in other States were expected to have been heard and acted on but were put on hold until sometime later in 2013 or early 2014.
skies the limit here,he medical Marijuana industry could reach nearly $9 billion nationwide in five years, as more states in the United States clear the way to likely legalize marijuana for medicinal purposes
"owned fifteen U.S. patents, nine foreign patents, five U.S. patent applications and numerous international patent applications designating over 100 foreign countries with claims relating to our sustained release delivery matrix system, systems containing drug preparations, uses of the systems for various treatment therapies and addiction therapeutic program. The patents were to expire between 2015 and 2018".
Easton Pharmaceuticals is based in Toronto, Ontario, Canada with a manufacturing partner in a 100,000 sq. ft. FDA approved facility in New Jersey, United States."
NOW READ THIS:
INSIDERS,"CEO & V.P. of AXXESS PHARMACEUTICAL AXXE ($1.00 pps) EACH OWN 10,000,000 RESTRICTED SHARES, THAT IS 20,000,000.. "
Neil Mellor is a pharmaceutical executive with over 25 years experience in sales, marketing and business development, both in Canada and Europe. Neil's leadership has driven the successful performance of some of the world's biggest prescription drug brands for companies like GSK-GlazoSmithKline, Pfizer, and Abbott Laboratories.
Neil has extensive experience managing products in the CNS, cardiovascular and GI areas. Some of Neil's greatest success in the market came during his management of Pantoloc (Protonix), which attained sales of +$300m and became the #2 pharmaceutical product in Canada.
As business development lead at Thought Leader Select, Neil routinely engages with companies to understand their challenges and strategic needs for better engagement and compliance in their activities with thought leaders in medicine. Neil is passionate about Thought Leader Select's work as a bridge that facilitates collaboration among industry companies and the health care community, insuring that better patient and public health result with each interaction.
Industry Expertise:
1)Biotechnology 2)Pharmaceuticals 3)Health Care - Services 4)Medical Devices 5)Health Care - Providers